alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2017121EN.01003801.xml

| 18.4.2017 | EN | Official Journal of the European Union | C 121/38 |
| --- | --- | --- | --- |

18.4.2017

EN

Official Journal of the European Union

C 121/38

---

Action brought on 13 February 2017 — Gelinova Group v EUIPO — Cloetta Italia (galatea...è naturale)

(Case T-90/17)

(2017/C 121/56)

Language in which the application was lodged: Italian

Parties

Parties

Applicant: Gelinova Group Srl (Tezze di Vazzola, Italy) (represented by: A. Tornato and D. Hazan, lawyers)

Applicant:

Defendant: European Union Intellectual Property Office (EUIPO)

Defendant:

Other party to the proceedings before the Board of Appeal: Cloetta Italia Srl (Cremona, Italy)

Other party to the proceedings before the Board of Appeal:

Details of the proceedings before EUIPO

Details of the proceedings before EUIPO

Applicant for the trade mark at issue: Applicant

Applicant for the trade mark at issue:

Trade mark at issue: EU figurative mark containing the word elements ‘galatea...è naturale’ — Application for registration No 13 187 695

Trade mark at issue:

Procedure before EUIPO: Opposition proceedings

Procedure before EUIPO

Contested decision: Decision of the Second Board of Appeal of EUIPO of 12 December 2016 in Case R 207/2016-2

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the contested decision; |
| --- | --- |

—

annul the contested decision;

| — | order EUIPO to pay the costs. |
| --- | --- |

—

order EUIPO to pay the costs.

Plea in law

Plea in law

| — | Infringement of Article 8(1)(b) of Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 8(1)(b) of Regulation No 207/2009.

---
# National Biotechnology Week

For thousands of years, man has been utilizing and modifying biological processes to improve man's quality of life. Scientific advances have enabled biotechnology to play an increasingly large role in the development of new products that enhance all areas of our lives.

In the battle against disease, our ever-increasing knowledge of cellular and genetic processes continues to improve the quality of our health care. Biotechnology has contributed to the development of vaccines, antibiotics, and other drugs that have saved or prolonged the lives of millions of people. Insulin, which is vital in the treatment of diabetes, can now be produced inexpensively and in large quantities through the use of genetically engineered bacteria. In addition, exciting gains in the understanding of the human body's genetic code show significant promise in finding treatments and eventually a cure for many diseases. This technology is now central to the research being conducted on diseases such as cancer, diabetes, epilepsy, multiple sclerosis, heart and lung disease, Alzheimer's disease, and Acquired Immune Deficiency Syndrome (AIDS).

Consumers enjoy continual improvements to the quality and quantity of our Nation's food supply. Genetic engineering will enable farmers to modify crops so that they will grow on land that was previously considered infertile. In addition, it will enable farmers to grow produce with enhanced nutritional value. We also are benefiting from crops that resist plant diseases and insects, thus reducing the use of pesticides.

The environmental benefits of biotechnology can be realized through the increased ability of manufacturers to produce their products with less energy, pollution, and waste. In addition, the development of new biotechnology promises to improve our ability to clean up toxic substances from soil and water and improve waste management techniques.

Our Nation stands as a global leader in research and development, in large part because of our successes in understanding and utilizing the biological processes of life. The field of biotechnology is important to the quality of our lives, the protection of our environment, and the strength of our economy. We must continue to be leaders in the pursuit of knowledge and technology, and we must be vigilant to ensure that new technologies are regulated and used responsibly towards achieving noble goals.

                        NOW, THEREFORE, I, GEORGE W. BUSH, President of the United States of America, by virtue of the authority vested in me by the Constitution and laws of the United States, do hereby proclaim May 13 through May 19, 2001, as National Biotechnology Week. I call upon the people of the United States to observe this week with appropriate programs, ceremonies, and activities.                              ( print page 28046)    

IN WITNESS WHEREOF, I have hereunto set my hand this sixteenth day of May, in the year of our Lord two thousand one, and of the Independence of the United States of America the two hundred and twenty-fifth.

[FR Doc. 01-12966

Billing code 3195-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Defense

###### Department of the Air Force

The Automatic Target Recognition (ATR) for Sensor Meeting will meet in Boston, Massachusetts on May 24-25, 2001 from 8 a.m. to 5 p.m.

The purpose of the meeting is to receive briefings and discuss the direction of the study. The meeting will be closed to the public in accordance with section 552b(c) of Title 5, United States Code, specifically subparagraphs (1) and (4) thereof.

For further information, contact the HQ USAF Scientific Advisory Board Secretariat at (703) 697-8404.

Janet A. Long,

Air Force Federal Register Liaison Officer.

[FR Doc. 01-12447 Filed 5-16-01; 8:45 am]

BILLING CODE 5001-05-P
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1941 Introduced in House (IH)]

<DOC>

116th CONGRESS
  1st Session
                                H. R. 1941

    To amend the Outer Continental Shelf Lands Act to prohibit the 
  Secretary of the Interior including in any leasing program certain 
                planning areas, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 28, 2019

Mr. Cunningham (for himself, Mr. Rooney of Florida, Mr. Lowenthal, Mr. 
    Huffman, Mr. Van Drew, Mr. Hastings, Mr. Rouda, Mr. Pappas, Mr. 
   Gallego, Ms. Velazquez, Ms. Hill of California, Mr. Panetta, Ms. 
   Ocasio-Cortez, Mr. Beyer, Ms. Wasserman Schultz, Ms. Jayapal, Ms. 
    Shalala, Ms. Haaland, Mr. Johnson of Georgia, Mr. McEachin, Mr. 
 Carbajal, Mr. Kim, Ms. Pingree, Mr. Ted Lieu of California, Mr. Case, 
     Mr. Schiff, Ms. Castor of Florida, Ms. DeGette, Mr. Levin of 
    California, Mr. Soto, and Mr. Cox of California) introduced the 
    following bill; which was referred to the Committee on Natural 
                               Resources

_______________________________________________________________________

                                 A BILL

 
    To amend the Outer Continental Shelf Lands Act to prohibit the 
  Secretary of the Interior including in any leasing program certain 
                planning areas, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Coastal and Marine Economies 
Protection Act''.

SEC. 2. PROHIBITION ON LEASING IN CERTAIN PLANNING AREAS.

    Section 18 of the Outer Continental Shelf Lands Act is amended by 
redesignating subsections (g) and (h) as subsections (h) and (i) 
respectively, and by inserting after subsection (f) the following:
    ``(g) The Secretary shall not include in any leasing program under 
this section any area within the Atlantic Region planning areas or the 
Pacific Region planning areas, as such planning areas are described in 
the document entitled `Draft Proposed Program Outer Continental Shelf 
Oil and Gas Leasing Program 2019-2024', dated January 2018.''.
                                 <all>
```
Exhibit
31.1





Section
302 Certification of Chief Executive Officer and Chief Financial
Officer





I, David
Taigen, certify that:





1.   I
have reviewed this quarterly report on Form 10-Q of Corporate Outfitters,
Inc.





2.   Based
on my knowledge, this quarterly report does not contain any untrue statement of
a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances   under which such
statements were made, not misleading with respect to the period covered by this
quarterly report;





3.   Based
on my knowledge, the financial statements, and other financial information
included in this quarterly report, fairly present in all material respects the
financial condition, results of operations  and cash flows of the
registrant as of, and for, the periods presented in this quarterly
report;





4.   The
registrant's other certifying officers and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and have:





a)   designed
such disclosure controls and procedures to ensure


that
material information relating to the registrant, including its


consolidated
subsidiaries, is made known to us by others within


those
entities, particularly during the period in which this


quarterly
report is being prepared;


b)   evaluated
the effectiveness of the registrant's disclosure


controls
and procedures as of a date within 90 days prior to


the
filing date of this quarterly  report
(the  "Evaluation


Date");
and


c)   presented
in this quarterly report our conclusions about the


effectiveness
of the disclosure controls and procedures based on


our
evaluation as of the Evaluation Date;





5.   The
registrant's other certifying officers and I have disclosed, based on our most
recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent
functions):





a)   all
significant  deficiencies in the design or operation of


internal
controls which could adversely affect the registrant's


ability
to record, process, summarize and report financial data


and
have identified for the registrant's auditors any material


weaknesses
in internal controls; and


b)   any
fraud, whether or not material, that involves management


or
other employees who have a significant role in the registrant's


internal
controls.





6.   The
registrant's other certifying officers and I have indicated in this quarterly
report whether or not there were significant changes in  internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant efficiencies and material
weaknesses.


Date:
July 28, 2008





/s/
David Taigen


Dave
Taigen


Chief
Executive Officer and


Chief Financial Officer
# C_2005183EN.01001901.xml

| 26.7.2005 | EN | Official Journal of the European Union | C 183/19 |
| --- | --- | --- | --- |

26.7.2005

EN

Official Journal of the European Union

C 183/19

---

Information communicated by Member States regarding State aid granted under Commission Regulation (EC) No 2204/2002 of 5 December 2002 on the application of Articles 87 and 88 of the EC Treaty to State aid for employment

(2005/C 183/08)

(Text with EEA relevance)

Aid No: XE 07/03

Member State: France

Region: Alsace

Title of aid scheme or name of company receiving an individual award: Aid for the takeover of firms in difficulty

Legal basis: Article L-1511-2 du CGTC

Article L-1511-2 du CGTC

Délibération no 047/02 du CRA

Délibération no

Annual expenditure planned or overall amount of individual aid granted to the company: Annual overall amount: EUR 3 million

Maximum aid intensity: In conformity with Article 4(2-5) and Articles 5 and 6 of the Regulation

Date of implementation: Beginning of 2004

Duration of scheme or individual aid award: Until 31 December 2006

Objective of aid: Article 4 Creation of employment

Economic sector(s) concerned: All Community sectors (1) eligible for employment aid

1

Name and address of the granting authority:

| Conseil régional d'Alsace |
| --- |
| M. Adrien Zeller, Président |
| 35 Avenue de la Paix |
| F-67070 Strasbourg Cedex |

Conseil régional d'Alsace

M. Adrien Zeller, Président

35 Avenue de la Paix

F-67070 Strasbourg Cedex

Other information: If the scheme is co-financed by Community funds, please add the following sentence:

The aid scheme is co-financed under (reference).

Not applicable.

Aid subject to prior notification to the Commission

The measure excludes awards of aid or requires prior notification to the Commission of awards of aid in conformity with Article 9 of the Regulation.

---

(1)  With the exception of the shipbuilding sector and of other sectors which are the subject of special rules in regulations and directives governing all State aid within the sector.

1

---
# C_2017424EN.01004801.xml

| 11.12.2017 | EN | Official Journal of the European Union | C 424/48 |
| --- | --- | --- | --- |

11.12.2017

EN

Official Journal of the European Union

C 424/48

---

Action brought on 3 October 2017 — Minera Catalano Aragonesa and Luengo Martínez v Commission and SRB

(Case T-678/17)

(2017/C 424/70)

Language of the case: Spanish

Parties

Parties

Applicants: Minera Catalano Aragonesa, SA (Ariñoteruel, Spain) and Ángel Luengo Martínez (Zaragoza, Spain) (represented by: R. Montejo Pérez, F. Ferrara and F. Banti, lawyers)

Applicants:

Defendants: European Commission and Single Resolution Board

Defendants:

Form of order sought

Form of order sought

The applicants claim that the General Court should:

| — | Annul the decisions of 7 June 2017 of the Single Resolution Board (No SRB/EES/2017/08) and of the European Commission (No 1246); |
| --- | --- |

—

Annul the decisions of 7 June 2017 of the Single Resolution Board (No SRB/EES/2017/08) and of the European Commission (No 1246);

| — | Order the Single Resolution Board and the European Commission to pay the costs. |
| --- | --- |

—

Order the Single Resolution Board and the European Commission to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

The pleas in law and main arguments are similar to those put forward in Cases T-478/17, Mutualidad de la Abogacía and Hermandad Nacional de Arquitectos Superiores y Químicos v Single Resolution Board, T-481/17, Fundación Tatiana Pérez de Guzmán el Bueno and SFL v Single Resolution Board, T-482/17, Comercial Vascongada Recalde v Commission and Single Resolution Board, T-483/17, García Suárez and Others v Commission and Single Resolution Board, T-484/17, Fidesban and Others v Single Resolution Board, T-497/17, Sáchez del Valle and Calatrava Real State 2015 v Commission and Single Resolution Board, and T-498/17, Pablo Álvarez de Linera Granda v Commission and Single Resolution Board.

Mutualidad de la Abogacía and Hermandad Nacional de Arquitectos Superiores y Químicos

Single Resolution Board

Fundación Tatiana Pérez de Guzmán el Bueno and SFL

Single Resolution Board

Comercial Vascongada Recalde

Commission and Single Resolution Board

García Suárez and Others

Commission and Single Resolution Board

Fidesban and Others

Single Resolution Board

Sáchez del Valle and Calatrava Real State 2015

Commission and Single Resolution Board

Pablo Álvarez de Linera Granda

Commission and Single Resolution Board.

---
EXHIBIT 32

      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Marc Gagnon, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, Sterling
Exploration,  Inc.'s  Quarterly Report on Form 10-Q for the fiscal quarter ended
September  30, 2008 fully  complies  with the  requirements  of Section 13(a) or
15(d) of the Securities  Exchange Act of 1934 and that information  contained in
such Quarterly Report on Form 10-Q fairly presents in all material  respects the
financial condition and results of operations of Sterling Exploration, Inc.


Date: November 11, 2008               By: /s/ Marc Gagnon
                                         ---------------------------------------
                                      Name:  Marc Gagnon
                                      Title: Chief Executive & Financial Officer
EXHIBIT 5

FREDRIKSON & BYRON, P.A.
200 South Sixth Street, Suite 4000
Minneapolis, Minnesota 55402-1425
Telephone: (612) 492-7000
Facsimile: (612) 492-7077

June 14, 2005

Dotronix, Inc.
160 First Street SE
New Brighton, MN 55112

| | Re:   Registration Statement on Form S-8
| | ----------------------------------------

Ladies/Gentlemen:

We are acting as corporate
counsel to Dotronix, Inc. (the Company) in connection with the original registration by the Company on Form S-8 (the
Registration Statement) under the Securities Act of 1933, as amended (the Act), of options and 250,000
shares (the Shares) of Common Stock issuable pursuant to the Companys 1999 Stock Incentive Plan (the
Plan).

In acting as such counsel and
for the purpose of rendering this opinion, we have reviewed copies of the following, as presented to us by the Company:

|1. |  | The Companys Articles of Incorporation, as amended.
|-- |  | ----------------------------------------------------

|2. |  | The Companys Bylaws, as amended.
|-- |  | ---------------------------------

|3. |  | Certain corporate resolutions adopted by the Board
of Directors and shareholders of the Company pertaining to the adoption and approval of the Plan and the increase in the number of
shares reserved for issuance thereunder.
|-- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|4. |  | The Plan.
|-- |  | ---------

|5. |  | The Registration Statement.
|-- |  | ---------------------------

Based on, and subject to, the
foregoing and upon representations and information provided by the Company or its officers or directors, it is our opinion as of
this date that:

---

June 14, 2005
Page 2

|1. |  | The Shares are validly authorized by the
Companys Articles of Incorporation, as amended.
|-- |  | -----------------------------------------------------------------------------------------

|2. |  | Upon issuance and delivery of the Shares against
receipt by the Company of the consideration for the Shares pursuant to the terms of the Plan, the Shares will be validly issued,
fully paid and nonassessable.
|-- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We hereby consent to the
filing of this opinion as an exhibit to the Registration Statement.

| |                 |                          |  |                       | 
| | --------------- | ------------------------ |  | --------------------- | 
| |                 | Very truly yours,       
|
| |                 | FREDRIKSON & BYRON, P.A.
| |                 | By                       |  | /s/   Robert K. Ranum | 
| |                
| | Robert K. Ranum |                         

---
# C_2017277EN.01005201.xml

| 21.8.2017 | EN | Official Journal of the European Union | C 277/52 |
| --- | --- | --- | --- |

21.8.2017

EN

Official Journal of the European Union

C 277/52

---

Action brought on 29 June 2017 — Karl Storz v EUIPO (3D)

(Case T-413/17)

(2017/C 277/75)

Language of the case: English

Parties

Parties

Applicant: Karl Storz GmbH & Co. KG (Tuttlingen, Germany) (represented by: S. Gruber, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (EUIPO)

Defendant:

Details of the proceedings before EUIPO

Details of the proceedings before EUIPO

Trade mark at issue: International registration designating the European Union in respect of the figurative mark containing the word elements ‘3D’ — International registration designating the European Union No 1 272 627

Trade mark at issue:

Contested decision: Decision of the Second Board of Appeal of EUIPO of 11 April 2017 in Case R 1502/2016-2

Contested decision

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the Second Board of Appeal of the European Union Intellectual Property Office of 11 April 2017 in Case R 1502/2016-2 and register the trade mark ‘3D’, IR 1 272 627, designating the European Union for all the goods applied for including the goods which are still affected by the contested decision; |
| --- | --- |

—

annul the decision of the Second Board of Appeal of the European Union Intellectual Property Office of 11 April 2017 in Case R 1502/2016-2 and register the trade mark ‘3D’, IR 1 272 627, designating the European Union for all the goods applied for including the goods which are still affected by the contested decision;

| — | order EUIPO to pay the costs. |
| --- | --- |

—

order EUIPO to pay the costs.

Pleas in law

Pleas in law

| — | Infringement of Article 7(1)(b) in conjunction with Article 7(2) of the Regulation No 207/2009; |
| --- | --- |

—

Infringement of Article 7(1)(b) in conjunction with Article 7(2) of the Regulation No 207/2009;

| — | Infringement of Article 7(1)(c) in conjunction with Article 7(2) of the Regulation No 207/2009. |
| --- | --- |

—

Infringement of Article 7(1)(c) in conjunction with Article 7(2) of the Regulation No 207/2009.

---